Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas
Five-year progression-free survival approached 40% and 5-year overall survival was over 50% in the study. Treatment-related mortality ranged from about 8% to 24%, depending on the donor type.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Health | Hematology | Lymphoma | Study | T-cell Lymphoma | Transplants